Janssen Presents New Data that could Set Anti-Inflammatory Drug Apart

Janssen’s Tremfya, an IL-23 inhibitor, is showing an ability to separate itself from AbbVie’s Skyrizi in preventing the activation of cells that drive inflammation.

On Wednesday, Janssen presented data from the in vitro MODIF-Y studies that support a hypothesis that highlights the differentiated mechanism of action of Tremfya (guselkumab) from Skyrizi (risankizumab).